Article Text

PDF
Long non-coding RNA chromogenic in situ hybridisation signal pattern correlation with breast tumour pathology
  1. Zhouwei Zhang1,2,
  2. Donald L Weaver1,3,4,
  3. Daniel Olsen3,
  4. James deKay3,
  5. Zhihua Peng1,
  6. Takamaru Ashikaga4,5,
  7. Mark F Evans1,4
  1. 1Department of Pathology and Laboratory Medicine, University of Vermont College of Medicine, Burlington, Vermont, USA
  2. 2Laboratory of Cancer Epigenetics, Van Andel Research Institute, NE Grand Rapids, Michigan, USA
  3. 3Department of Pathology and Laboratory Medicine, University of Vermont Medical Center, Burlington, Vermont, USA
  4. 4University of Vermont Cancer Center, Burlington, Vermont, USA
  5. 5Biostatistics Unit, University of Vermont College of Medicine, Burlington, Vermont, USA
  1. Correspondence to Dr Mark F Evans, Department of Pathology and Laboratory Medicine, University of Vermont College of Medicine, 89 Beaumont Avenue, Burlington, VT 05405, USA; mark.evans{at}uvm.edu

Abstract

Aim Long non-coding RNAs (lncRNAs) are potential biomarkers for breast cancer risk stratification. LncRNA expression has been investigated primarily by RNA sequencing, quantitative reverse transcription PCR or microarray techniques. In this study, six breast cancer-implicated lncRNAs were investigated by chromogenic in situ hybridisation (CISH).

Methods Invasive breast carcinoma (IBC), ductal carcinoma in situ (DCIS) and normal adjacent (NA) breast tissues from 52 patients were screened by CISH. Staining was graded by modified Allred scoring.

Results HOTAIR, H19 and KCNQ1OT1 had significantly higher expression levels in IBC and DCIS than NA (p<0.05), and HOTAIR and H19 were expressed more strongly in IBC than in DCIS tissues (p<0.05). HOTAIR and KCNQ101T were expressed in tumour cells; H19 and MEG3 were expressed in stromal microenvironment cells; MALAT1 was expressed in all cells strongly and ZFAS1 was negative or weakly expressed in all specimens.

Conclusion These data corroborate the involvement of three lncRNAs (HOTAIR, H19 and KCNQ1OT1) in breast tumourigenesis and support lncRNA CISH as a potential clinical assay. Importantly, CISH allows identification of the tissue compartment expressing lncRNA.

  • BREAST CANCER
  • IN SITU HYBRIDISATION
  • TUMOUR MARKERS

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.